After today's fiasco, I more clearly understood that stem cells medicine is still very far from the market, at least for companies the sizes of Pluristem or Mesoblast. The lack of real partners who would invest money was always alarming, and today the reasons for this are absolutely clear. With Yaki's pitiful experience in this business, such partners are needed for the company like air. He should be replaced by a professional immediately. But my question about this was not read out today.LOL The other three indications do not cause much enthusiasm for me. COVID-19 will lose 90% of its relevance long before they are over the study, HCT needs years and years before it hits the market, if ever and with muscle regeneration, there is a lot of uncertainty, this indication is not as significant as CLI. My aunt in Israel, who broke her hip neck at the age of 83, recovered without any stem cells and now moves quite normally.I didn’t sell, but if I’m lucky to see $ 10-11 someday, I out immediately.All of their intellectual property, including the production technology will go as a free application if we lucky enough to see the acquisition of the company, say for $400- 500 m. But something tells me that there is no line of buyers at their door.
News 
Market Data 
Discover 
AI
